Psoriasis Clinical Trials

Showing 541-560 of 1,026 trials

PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors

NCT04821206

This prospective, non-interventional, research registry is designed to study the comparative safety and comparative effectiveness of approved Jak Inhibitors treatment for RA-PsA-SpA in a cohort of patients and theirs controls cared for by rheumatologists across Latin América (LA).

Arthritis, RheumatoidArthritis, PsoriaticSpondyloarthritis

Liga Panamericana de Asociaciones de Reumatologia (PANLAR)3,000 participantsStarted Mar 2021

CABA, Buenos Aires, Argentina • Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina

COMPLETEDPhase 1

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis

NCT02195349

This study is a phase I, randomised, double blind (sponsor unblinded), placebo-controlled, single ascending dose study GSK2831781 administered by IV. GSK2831781 is a humanized Antibody Dependent Cell Cytotoxicity (ADCC) enhanced monoclonal afucosylated antibody that is specific to the Lymphocyte Activation Gene-3 (LAG-3) protein. This is the first administration of GSK2831781 in humans and will evaluate in two parts the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of single IV doses of GSK2831781 administered to healthy subjects previously vaccinated with Bacillus Calmette Guérin (BCG) (Part A delayed type hypersensitivity \[DTH\] cohorts) and patients with plaque psoriasis (Part B). The inclusion of DTH and psoriasis subjects to explore the mechanism in biopsies and clinical response endpoints in these populations, as well as investigate systemic biomarkers will provide useful information prior to conducting studies in other immune-inflammatory disease which will involve more invasive tissue biopsies. Measuring the pharmacology of GSK2831781 using the depletion of LAG-3+ T-cells in skin biopsies from Tuberculin Purified Protein Derivative (PPD) skin challenge and lesional skin biopsies from patients with psoriasis, will be helpful in understanding of the dose response relationship, which will be important for designing future studies in immuno-inflammatory diseases, including psoriasis. Approximately 67 subjects will be enrolled to complete dosing and critical assessments. The subject numbers will be split to approximately 40 healthy subjects (Part A) and 27 patients with psoriasis (Part B).

Psoriasis

GlaxoSmithKline67 participantsStarted Jul 2014

Bonn, North Rhine-Westphalia, Germany • Berlin, Germany • London, United Kingdom

PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis

Related Searches

Body PSOriasis: Long-term Relapse CONTROL

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

Evaluation of Patient Satisfaction and Therapeutic Impact Regarding Joint Consultation Rheumatologist/Dermatologist

Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

The Norwegian Drug Monitoring Study

Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis

Low Dose Naltrexone for Chronic Pain From Arthritis

A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis

PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

Effectiveness of Artificial Balneotherapy, Phototherapy and Artificial Balneophototherapy in the Treatment of Psoriasis

Efficacy and Safety of Expanded UCMSCs On Patients With Moderate to Severe Psoriasis

Ultraviolet Radiation Forecasting Based Heliotherapy For Psoriasis in Bangkok, Thailand

The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis

Sonographic Analysis of Nails in Psoriatic Arthritis and Healthy Controls

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

CP-690-550 Ointment For Chronic Plaque Psoriasis

Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease

Central Pain Mechanisms in Patients With Hand-Osteoarthritis, Psoriatic Arthritis and Healthy Controls